2 analysts' median target is $138[FMP target], stock is $113, +22.6% upside potential. After Q4 +5.7% EPS beat[FMP earnings], the stock moved +0.8%.
B+ = MoonshotScore 56[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $2.3B[FMP est], EPS $1.61[FMP est]. 8 consecutive quarters of beat[FMP earnings].
Q4 EPS +5.7% beat[FMP] but the stock +0.8% D+1[FMP D+1]. Wetteny Joseph promised $161.0M CapEx + a sequential decline in Q4 during the Q4 earnings call[Wetteny Joseph capex transcript].
Watchlist
Dermatology Franchise Growth
dermatology_franchise_growth
Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built.
"Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Companion Animal Diagnostics Growth
companion_animal_diagnostics_growth
Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits.
"Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Simparica Franchise Growth
simparica_franchise_growth
The Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets.
"Our Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Livestock Growth
livestock_growth
We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally.
"We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Oa Pain Decline
oa_pain_decline
Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth.
"Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Simparica Trio Performance
simparica_trio_performance
Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic.
"Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic."
- Kristin Peck - Q4 FY25 Earnings Call - February 12, 2026
Stock Expert AI - Methodology
9-pillar methodology. Gross Margin and Cash Runway strong. Operating Leverage weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
Q4 (February 12, 2026): EPS $1.48 vs $1.40 est[FMP], +5.7% beat. D+1 movement: +0.8%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q4: EPS $1.48 vs $1.40 beat[FMP], stock +0.8% D+1[FMP]. Wetteny Joseph Q4 transcript: "Looking ahead to 2026, we are guiding to a range of 3% to 5% organic operational revenue growth and expect 3% to 6% organic operational growth in adjusted net income."[Wetteny Joseph].
"Looking ahead to 2026, we are guiding to a range of 3% to 5% organic operational revenue growth and expect 3% to 6% organic operational growth in adjusted net income."
- Wetteny Joseph, CFO - Q4 FY25 Earnings Call - February 12, 2026
No RPO/backlog concentration disclosed in Q4 earnings call.
Q4 CapEx $161.0M[FMP cashflow]. Q4 op margin 34.6%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.61[FMP], CapEx threshold "below $161.0M"[Wetteny Joseph]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This ZTS (ZTS) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.